Navigation Links
Life Science Alley: R&D Makes German Medical Technologies Top in Europe
Date:12/8/2008

BERLIN, December 8 /PRNewswire/ -- Germany is Europe's largest market for medical devices. Total industry revenue in 2007 amounted to EUR 17.3 billion - a nearly 7 percent increase on 2006 figures. Investors looking to enter the German and European markets can learn about Germany at Life Science Alley, the largest convention of life science industry professionals in the American Midwest. The conference takes place December 10, 2008 in Minneapolis, Minnesota.

Germany's research landscape is making its medical technologies some of the most renowned and trusted worldwide. The country's advanced R&D network ensures that both patients and practitioners have access to the latest medical technologies.

Currently German medical technology companies spend about 9 percent of sales revenue on R&D. As a result, products under three years old account for 32 percent of industry revenue in Germany. Furthermore, Germany is number two in the world in patent applications in medical technologies.

Demographic developments suggest that Germany will remain strong in medical technologies in coming years. By 2015 it is expected that nearly one fifth of Germany's population will be over age 65, increasing the need for advanced medical technologies and health care.

Existing clusters of manufacturers, research institutes, and clinics allow companies of all sizes the chance to use Germany's investment conditions to maximize earnings quickly and efficiently. The availability of investment incentives as well as R&D and labor incentives also makes the country an attractive investment location.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. It can be found at booth 301 at Life Science Alley.

    Media Contact:
    Eva He
'/>"/>
SOURCE Invest in Germany GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4FAA Grants Comment Extension at the Request of AMA 2ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
... Start of Q4 2008 , - Evaluation of strategic alternatives ... RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext ... reduction-in-force in an effort to extend its remaining cash and ... a reduction implemented in October 2008. In all, the ...
... Jan. 5 LightLab Imaging Inc. today,announced ... past year that are,the culmination of sustained ... These advances significantly increase the Company,s leadership,position ... OCT is a new,high-resolution, high-speed imaging ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3
(Date:7/28/2014)... U.S. cities that have seen an increase in so-called ... closures, overwhelmed storm drains and compromised infrastructure--are on the ... , This nuisance flooding, caused by rising sea levels, ... and 925 percent since the 1960s. , The report, ... the United States, also finds Annapolis and Baltimore, Maryland, ...
(Date:7/28/2014)... found that 73 percent of adult survivors of childhood ... syndrome and related health problems by failing to follow ... issue of the journal Cancer . , Almost ... cancer in the study had metabolic syndrome, an umbrella ... abdominal obesity, elevated triglyceride and other abnormalities that often ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2
... during deployments, U.S. Army units can gain tactical ... and post-conflict operations, and boost overall mission success, ... The study finds that commanders have not ... despite the effect environmental conditions can have on ...
... 23, 2008 Researchers at Sentara Cardiovascular Research Institute begin ... effectiveness of stents to open airways of patients with ... The EASE (Exhale Airway Stents for Emphysema) Trial ... to create new pathways to release trapped air from ...
... out of every three Americans is obese. These individuals are ... to other health problems, such as diabetes. ... the muscle. As a result, accumulated fat by-products inside ... of fat by-products, fat must either be oxidized (burned, as ...
Cached Biology News:Army can boost mission success by better managing 2Army can boost mission success by better managing 3Army can boost mission success by better managing 4Sentara begins international trial -- open at only 24 US locations 2For insulin sensitive overweight patients, 1 session of exercise improves metabolic health 2
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Prepared in distilled water....
Biology Products: